{
  "@context": {
    "dcterms": "http://purl.org/dc/terms/",
    "cito": "http://purl.org/spar/cito/",
    "deo": "http://purl.org/spar/deo/"
  },
  "@id": "https://hypothesis.bioagent.ai/pn4ugp2xav",
  "@type": "deo:FutureWork",
  "cito:usesDataFrom": [
    "https://doi.org/10.1186/s13041-024-01028-8",
    "https://doi.org/10.1371/journal.pone.0172640",
    "https://doi.org/10.1002/dad2.12391",
    "https://doi.org/10.1038/s41586-024-07701-9",
    "https://doi.org/10.1038/s41586-022-05535-x"
  ],
  "dcterms:references": [
    "# Mechanistic Hypothesis Connecting DOPAL's Anti-Oligomerization Effects and Dopamine-Mediated Neuroinflammation Reduction\n\n## 1. Background\nDOPAL (3,4-dihydroxyphenylacetaldehyde), a reactive dopamine metabolite produced by monoamine oxidase (MAO), has been demonstrated to decrease Aβ oligomerization in human neuroblastoma cells, thus reducing Aβ's cytotoxic effects. As shown in Abstract 1, L-DOPA administration significantly reduces neuroinflammation (microgliosis and astrogliosis) and decreases Aβ plaque burden in 5xFAD mice by upregulating clearance enzymes like NEP and ADAM17. Interestingly, Abstract 2 reveals that levodopa and dopamine agonists can enhance Aβ generation through D2 receptor-mediated β-arrestin 2 signaling, presenting an apparent paradox in dopamine's effects on Aβ pathology.\n\n## 2. Knowledge Gap\nWhile both the anti-oligomerization effects of DOPAL and the anti-inflammatory actions of dopamine analogues have been documented separately, the mechanistic link between these phenomena remains unexplored. Specifically, it is unknown how a dopamine metabolite that prevents Aβ oligomerization could influence neuroinflammatory processes, and whether this represents a coordinated neuroprotective pathway that balances increased Aβ production with reduced inflammatory responses to Aβ.\n\n## 3. Central Hypothesis\nDOPAL inhibits Aβ oligomerization by creating DOPAL-Aβ adducts that bind to microglial triggering receptor expressed on myeloid cells 2 (TREM2), activating an anti-inflammatory microglial phenotype that enhances Aβ clearance while suppressing pro-inflammatory responses.\n\n## 4. Proposed Mechanism\n1. Dopamine, either endogenous or from L-DOPA administration, is metabolized by MAO to produce DOPAL in the neuronal microenvironment.\n2. DOPAL reacts with monomeric Aβ peptides through aldehyde-mediated adduct formation at lysine residues, creating structurally modified DOPAL-Aβ adducts that resist oligomerization.\n3. These DOPAL-Aβ adducts have enhanced binding affinity for microglial TREM2 receptors compared to unmodified Aβ, preferentially activating the TREM2-DAP12 signaling cascade.\n4. TREM2 activation by DOPAL-Aβ adducts drives microglia toward a phagocytic, neuroprotective phenotype characterized by upregulated expression of Aβ-degrading enzymes (NEP, ADAM17) and reduced pro-inflammatory cytokine production.\n5. This DOPAL-mediated shift in microglial function creates a feedback loop that balances the increased Aβ production triggered by D2R-β-arrestin signaling (seen in Abstract 2) with enhanced clearance and reduced inflammatory damage.\n\n## 5. Testable Predictions\n1. Treatment of primary microglia or microglial cell lines with DOPAL-modified Aβ should induce higher TREM2 activation, increased expression of phagocytic markers, and lower pro-inflammatory cytokine release compared to treatment with unmodified Aβ.\n2. Cerebrospinal fluid from Parkinson's patients on L-DOPA therapy should show elevated levels of DOPAL-Aβ adducts that correlate negatively with markers of neuroinflammation and positively with TREM2 signaling markers.\n3. TREM2-deficient mouse models of AD treated with L-DOPA should fail to show the anti-inflammatory and plaque-reducing benefits observed in TREM2-sufficient mice, despite similar levels of DOPAL-Aβ adducts.\n\n## 6. Potential Experimental Approaches\n1. Develop an in vitro system using primary mouse microglia or BV-2 microglial cells exposed to either synthetic Aβ or DOPAL-modified Aβ. Assess TREM2 activation (by DAP12 phosphorylation), phagocytic activity (Aβ uptake), cytokine profiles, and expression of Aβ-degrading enzymes. Compare results between wild-type microglia and TREM2-knockout microglia to confirm pathway specificity.\n\n2. Generate a transgenic AD mouse model with inducible, microglia-specific TREM2 knockout crossed with 5xFAD mice. Compare the effects of L-DOPA treatment on neuroinflammation, Aβ pathology, and cognitive function between mice with intact microglial TREM2 and those with conditional TREM2 deletion. Analyze brain tissue for DOPAL-Aβ adducts, microglial phenotypic markers, and NEP/ADAM17 expression to validate the proposed mechanism.\n\nThis hypothesis offers a novel mechanistic framework connecting dopamine metabolism to Aβ processing and neuroinflammatory modulation through TREM2-mediated microglial reprogramming. It explains the seemingly contradictory effects observed in research where dopaminergic stimulation can increase Aβ production while simultaneously reducing inflammation and plaque burden. The proposed mechanism would have significant implications for both Alzheimer's and Parkinson's disease therapeutic approaches, suggesting that strategies targeting the DOPAL-TREM2 axis might provide neuroprotection through coordinated regulation of both Aβ processing and inflammatory responses."
  ],
  "dcterms:subject": [
    "amyloid beta",
    "inflammation"
  ],
  "dcterms:source": [
    "DOPAL, a dopamine metabolite, decreases Aβ oligomerization in human neuroblastoma cells, reducing the cytotoxic effects of Aβ.",
    "The paper indicates that dopamine analogues reduce neuroinflammation by suppressing immune responses"
  ],
  "dcterms:abstract": [
    "Dopamine plays important roles in cognitive function and inflammation and therefore is involved in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD). Drugs that increase or maintain dopamine levels in the brain could be a therapeutic strategy for AD. However, the effects of dopamine and its precursor levodopa (L‑DOPA) on Aβ/tau pathology in vivo and the underlying molecular mechanisms have not been studied in detail. Here, we investigated whether L‑DOPA treatment alters neuroinflammation, Aβ pathology, and tau phosphorylation in 5xFAD mice, a model of AD. We found that L‑DOPA administration significantly reduced microgliosis and astrogliosis in 5xFAD mice. In addition, L‑DOPA treatment significantly decreased Aβ plaque number by upregulating NEP and ADAM17 levels in 5xFAD mice. However, L‑DOPA‑treated 5xFAD mice did not exhibit changes in tau hyperphos‑phorylation or tau kinase levels. These data suggest that L‑DOPA alleviates neuroinflammatory responses and Aβ pathology but not tau pathology in this mouse model of AD.",
    "Although levodopa is the first-line medication for the treatment of Parkinson's disease (PD) showing unsurpassable efficiency, its chronic use causes dyskinesia. Accordingly, dopamine agonists are increasingly employed as monotherapy or in combination with levodopa to reduce the risk of motor complications. It is well recognized that patients with PD often exhibit cognitive deficits. However, clinical and animal studies assessing the effects of dopaminergic medications on cognition are controversial. Amyloid-β (Aβ) is one of the major hallmarks of Alzheimer's disease (AD), leading to progressive memory loss and cognitive deficit. Interestingly, the abnormal accumulation of Aβ is also detected in PD patients with cognitive deficits. Evidence indicated that levodopa induced a mild increase of Aβ plaque number and size in the brain of AD mouse. However, the underlying mechanism is unclear. Here we present that both levodopa and piribedil enhance the generation of Aβ and the activity of γ-secretase in human neuronal cells and primary neurons isolated from AD mouse. This effect was reduced by either the antagonism or the knockdown of dopamine D2 receptor (D2R). We further showed that in the cells expressing β-arrestin 2-biased D2R mutant, piribedil promoted cellular Aβ production to the extent comparable to the wild-type D2R whereas this activity was absent in those with G protein-biased D2R mutant. Moreover, the knockdown of β-arrestin 2 attenuated the increases of Aβ generation and γ-secretase activity mediated by levodopa or piribedil. Thus, our study suggests that targeting D2R-mediated β-arrestin function may have potential risk in the modulation of Aβ pathology.",
    "[18F]AZD4694 is an amyloid beta (Aβ) imaging agent used in several observational studies and clinical trials. This study assessed 146 individuals evaluated with [18F]AZD4694 at baseline and a 2‐year follow‐up, revealing longitudinal patterns of Aβ accumulation. Results showed that cognitively unimpaired older adults displayed subtle Aβ accumulation, while Aβ positive cases exhibited greater increases, underscoring the agent’s potential to monitor Aβ levels in clinical settings.",
    "For healthspan and lifespan, ERK, AMPK and mTORC1 represent critical pathways and inflammation is a centrally important hallmark. Here we examined whether IL-11, a pro-inflammatory cytokine of the IL-6 family, has a negative effect on age-associated disease and lifespan.",
    "Tissue regeneration requires coordination between resident stem cells and local niche cells. Here we identify that senescent cells are integral components of the skeletal muscle regenerative niche that repress regeneration at all stages of life. Our results provide a technique for isolating in vivo senescent cells, define a senescence blueprint for muscle, and uncover unproductive functional interactions between senescent cells and stem cells in regenerative niches."
  ]
}